Molbio Diagnostics gets $85 mn from Temasek

CHENNAI: Goa-based Molbio Diagnostics, which provides innovative solutions for universal access to high-quality healthcare, announced that Temasek has invested $85 million in the company.

Molbio is known for its game-changing Truenat® technology – a point-of-care, portable, battery-operated Real-Time PCR platform. Hailed globally as a high-impact breakthrough innovation, Truenat® is the world’s first point-of-care molecular diagnostic platform to get endorsed by the World Health Organisation (WHO) as a replacement to smear microscopy for the diagnosis of Tuberculosis.

The technology can be deployed at all levels of the healthcare chain, including very remote and inaccessible areas, to provide early, rapid, and accurate diagnosis of infectious diseases, aiding in timely and appropriate treatment. The platform can test for over 40 diseases in addition to TB, including COVID-19, hepatitis, HIV, HPV, and vector-borne diseases like dengue, chikungunya and malaria.

The acclaimed ‘Truenat® Real-Time PCR’ has been deployed in over 5,000 testing centres across over 40 countries around the world, said a release.